...
首页> 外文期刊>The journal of clinical psychiatry >Revisiting monoamine oxidase inhibitors.
【24h】

Revisiting monoamine oxidase inhibitors.

机译:回顾单胺氧化酶抑制剂。

获取原文
获取原文并翻译 | 示例
           

摘要

Monoamine oxidase inhibitors (MAOIs) were among the first class of agents introduced for the treatment of depression. However, they have fallen out of favor among clinicians over the years, due mostly to an unfavorable safety profile, the need for restrictive dietary prohibitions, and the fear of hypertensive crisis. The development of a novel, transdermal MAOI system now offers clinicians an additional option for managing patients with unipolar, bipolar, atypical, and treatment-resistant depression.
机译:单胺氧化酶抑制剂(MAOIs)是用于治疗抑郁症的第一类药物。但是,由于安全性不佳,饮食限制饮食的需求以及对高血压危机的恐惧,多年来,它们在临床医生中一直不受欢迎。现在,新型透皮MAOI系统的开发为临床医生提供了治疗单相,双相,非典型和难治性抑郁症患者的另一种选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号